DDInter1323 DDInter899
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Octreotide {u} (Compound) resembles {v} (Compound) Polymyxin B
Octreotide {u} (Compound) resembles {v} (Compound) Bacitracin
Octreotide {u} (Compound) treats {v} (Disease) thymus cancer
Octreotide {u} (Compound) binds {v} (Gene) SSTR2
Octreotide {u} (Compound) palliates {v} (Disease) type 1 diabetes mellitus
Octreotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Octreotide {u} (Compound) causes {v} (Side Effect) Arthropathy
Octreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Octreotide (Compound) resembles Polymyxin B (Compound)
Octreotide (Compound) resembles Bacitracin (Compound)
Octreotide (Compound) treats thymus cancer (Disease)
Octreotide (Compound) binds SSTR2 (Gene)
Octreotide (Compound) palliates type 1 diabetes mellitus (Disease)
Octreotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Octreotide (Compound) causes Arthropathy (Side Effect)
Octreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human